Multi-omic machine learning predictor of breast cancer therapy response.
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin...
https://pubmed.ncbi.nlm.nih.gov/34875674/Actively Recruiting
Led by Royal Marsden NHS Foundation Trust · Updated on 2026-04-16
500
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying breast cancer in individuals receiving systemic anticancer treatments such as chemotherapy, targeted therapy, and immunotherapy before surgery. This observational study aims to collect breast cancer tissue, blood, and in some cases MRI scans and stool samples, to understand why some cancers respond well to treatments while others do not. The goal is to develop better ways to measure treatment response and identify patients at higher risk of cancer recurrence after surgery. Participants will provide samples of their tumor, blood, and sometimes stool before and during treatment. MRI scans may also be performed before and during therapy. These collected samples and imaging data will be analyzed deeply to identify molecular and genetic features of the cancer and patient that influence treatment response. The research will combine these findings to build predictors that help guide treatment decisions, such as identifying patients who may need alternative therapies or who might benefit from less intensive treatment. During the study, participants will undergo sequential tumor biopsies, blood draws, and possibly MRI scans according to the study protocol over a ten-year recruitment period. The research team will monitor adherence to timing for study procedures and evaluate molecular, imaging, and clinical data to correlate with treatment response and patient outcomes. This long-term observational study aims to improve understanding of breast cancer evolution during therapy and support development of future treatments.
CONDITIONS
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
B
BELIEVE Trial Manager
S
Sophie Cooke
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Royal Marsden NHS Foundation Trust
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 years during recruitment and follow-up
Participants undergo sequential tumour biopsies, blood samples, stool samples, and MRI scans to profile their breast cancer in detail and track treatment response.
Multiple visits for sample collection and imaging over several years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin...
https://pubmed.ncbi.nlm.nih.gov/34875674/Royal Marsden NHS Foundation Trust
Lead Sponsor